West Pharmaceutical Services (NYSE:WST) Updates FY 2025 Earnings Guidance

West Pharmaceutical Services (NYSE:WST) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share guidance of 6.000-6.200 for the period, compared to the consensus earnings per share estimate of 7.430. The company issued revenue guidance of $2.9 billion-$2.9 billion, compared to the consensus revenue estimate of $3.0 billion.

West Pharmaceutical Services Price Performance

Shares of West Pharmaceutical Services stock opened at $323.06 on Thursday. The firm has a market cap of $23.40 billion, a PE ratio of 47.93, a price-to-earnings-growth ratio of 19.31 and a beta of 1.01. The company’s fifty day simple moving average is $332.39 and its two-hundred day simple moving average is $315.13. The company has a quick ratio of 2.23, a current ratio of 3.00 and a debt-to-equity ratio of 0.07. West Pharmaceutical Services has a 12-month low of $265.00 and a 12-month high of $408.88.

West Pharmaceutical Services (NYSE:WST) last announced its earnings results on Thursday, February 13th. The medical instruments supplier reported $1.82 earnings per share for the quarter, beating analysts’ consensus estimates of $1.75 by $0.07. West Pharmaceutical Services had a net margin of 17.37% and a return on equity of 18.41%. As a group, equities analysts expect that West Pharmaceutical Services will post 6.67 EPS for the current year.

West Pharmaceutical Services Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, February 11th. Shareholders of record on Friday, February 7th were issued a $0.21 dividend. This represents a $0.84 dividend on an annualized basis and a yield of 0.26%. The ex-dividend date was Friday, February 7th. West Pharmaceutical Services’s dividend payout ratio (DPR) is presently 12.46%.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Citigroup assumed coverage on West Pharmaceutical Services in a research report on Wednesday, January 8th. They issued a “buy” rating and a $400.00 price target on the stock. Wolfe Research started coverage on West Pharmaceutical Services in a report on Friday, December 13th. They set a “peer perform” rating for the company. Bank of America increased their price objective on shares of West Pharmaceutical Services from $350.00 to $355.00 and gave the company a “buy” rating in a research report on Friday, December 13th. StockNews.com raised shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating in a report on Tuesday. Finally, UBS Group upgraded shares of West Pharmaceutical Services from a “neutral” rating to a “buy” rating and increased their price target for the company from $350.00 to $390.00 in a report on Thursday, December 12th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $403.75.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.